Stockreport

Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ... [Yahoo! Finance]

Allogene Therapeutics, Inc.  (ALLO) 
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
PDF Research and Development Expenses: $44.7 million in Q3 2024, including $5.6 million in noncash stock-based compensation. General and Administrative Expenses: $16.3 mi [Read more]